JP2014521738A - コロールおよびスタチンの併用 - Google Patents

コロールおよびスタチンの併用 Download PDF

Info

Publication number
JP2014521738A
JP2014521738A JP2014525542A JP2014525542A JP2014521738A JP 2014521738 A JP2014521738 A JP 2014521738A JP 2014525542 A JP2014525542 A JP 2014525542A JP 2014525542 A JP2014525542 A JP 2014525542A JP 2014521738 A JP2014521738 A JP 2014521738A
Authority
JP
Japan
Prior art keywords
statin
pharmaceutically acceptable
acceptable salt
corrole
transition metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014525542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521738A5 (enExample
Inventor
グロス ゼーヴ
アヴィラム ミハエル
ハバー アディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technion Research And Development Foundation Ltd
Original Assignee
Technion Research And Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research And Development Foundation Ltd filed Critical Technion Research And Development Foundation Ltd
Publication of JP2014521738A publication Critical patent/JP2014521738A/ja
Publication of JP2014521738A5 publication Critical patent/JP2014521738A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014525542A 2011-08-15 2012-08-14 コロールおよびスタチンの併用 Pending JP2014521738A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161523476P 2011-08-15 2011-08-15
US61/523,476 2011-08-15
PCT/IB2012/054124 WO2013024425A1 (en) 2011-08-15 2012-08-14 Combinations of corroles and statins

Publications (2)

Publication Number Publication Date
JP2014521738A true JP2014521738A (ja) 2014-08-28
JP2014521738A5 JP2014521738A5 (enExample) 2015-09-10

Family

ID=47003157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014525542A Pending JP2014521738A (ja) 2011-08-15 2012-08-14 コロールおよびスタチンの併用

Country Status (9)

Country Link
US (1) US9642860B2 (enExample)
EP (1) EP2744492A1 (enExample)
JP (1) JP2014521738A (enExample)
CN (1) CN103874490A (enExample)
BR (1) BR112014003529A2 (enExample)
CA (1) CA2845301A1 (enExample)
IL (1) IL230988A0 (enExample)
MX (1) MX2014001823A (enExample)
WO (1) WO2013024425A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637731B2 (en) * 2013-03-05 2017-05-02 Innovative Environmental Technologies, Inc. Heavy metal stabilization and methane inhibition during induced or naturally occurring reducing conditions in contaminated media
US9221699B2 (en) * 2013-03-05 2015-12-29 Innovative Environment Technologies, Inc. Inhibition of methane production during anaerobic reductive dechlorination
EP3730155A1 (en) * 2013-05-08 2020-10-28 Cedars-Sinai Medical Center Targeting corroles for tumor toxicity and mri
CN105440043A (zh) * 2015-08-06 2016-03-30 南京林业大学 一种冰片酯基咔咯衍生物及其制备方法
CN108752354A (zh) * 2018-06-11 2018-11-06 三峡大学 一种卟啉荧光染料的合成及其方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531468A (ja) * 2000-11-29 2004-10-14 マグラル・リミテッド スタチン副作用の処置
WO2009027965A1 (en) * 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
JP2009521526A (ja) * 2005-12-27 2009-06-04 ハンミ ファーム． シーオー．， エルティーディー． カンシル酸アムロジピン及びシンバスタチンを含む複合製剤及びその製造方法
WO2010053343A1 (es) * 2008-11-10 2010-05-14 Psicofarma S.A. De C.V. Proceso para la obtención de una composición de rosuvastatina cálcica y producto obtenido

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126426A0 (en) 1998-09-29 1999-05-09 Technion Res & Dev Foundation Process for the preparation of corroles several such new compounds including chiral derivatives and the use thereof
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
ATE472550T1 (de) 2001-07-02 2010-07-15 Technion Res & Dev Foundation Verfahren zur herstellung selektiv substituierter corrole und neue substituierte corrole
KR100918325B1 (ko) 2007-06-05 2009-09-22 충남대학교산학협력단 고콜레스테롤 치료용 복합제제 및 이의 제조방법
US20110098262A1 (en) 2008-01-31 2011-04-28 Yondim Moussa B H Corroles for neuroprotection and neurorescue
US8680266B2 (en) 2009-05-22 2014-03-25 California Institute Of Technology Metallocorroles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531468A (ja) * 2000-11-29 2004-10-14 マグラル・リミテッド スタチン副作用の処置
JP2009521526A (ja) * 2005-12-27 2009-06-04 ハンミ ファーム． シーオー．， エルティーディー． カンシル酸アムロジピン及びシンバスタチンを含む複合製剤及びその製造方法
WO2009027965A1 (en) * 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
WO2010053343A1 (es) * 2008-11-10 2010-05-14 Psicofarma S.A. De C.V. Proceso para la obtención de una composición de rosuvastatina cálcica y producto obtenido

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AM J GASTROENTEROL, vol. 106, JPN6016023465, January 2011 (2011-01-01), pages 71 - 7, ISSN: 0003341811 *
ARTERIOSCLER THROMB VASC BIOL., vol. 28, JPN6016023463, 2008, pages 18 - 20, ISSN: 0003341810 *
J LIPID RES., vol. 52, JPN6016023467, March 2011 (2011-03-01), pages 566 - 71, ISSN: 0003341812 *

Also Published As

Publication number Publication date
WO2013024425A1 (en) 2013-02-21
IL230988A0 (en) 2014-03-31
CN103874490A (zh) 2014-06-18
EP2744492A1 (en) 2014-06-25
MX2014001823A (es) 2014-08-21
US9642860B2 (en) 2017-05-09
US20140200204A1 (en) 2014-07-17
CA2845301A1 (en) 2013-02-21
BR112014003529A2 (pt) 2017-03-14

Similar Documents

Publication Publication Date Title
EP0741567B1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
HUP0303040A2 (hu) Készítmények és eljárások a plazma lipoprotein szintjének és a cardiovascularis betegségek kockázati tényezőinek csökkentésére
JP2023062198A (ja) 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物
JP2004210797A (ja) アムロジピン及びアトルバスタチンを含む治療用の組み合わせ
JP2001514224A (ja) アムロジピンとスタチン化合物を含む併用療法
KR20020019450A (ko) 암로디핀 및 아토르바스타틴의 상호 염
US9642860B2 (en) Combinations of corroles and statins
EP1919466B1 (en) Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative
EP3122348B1 (en) Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
KR20210139293A (ko) 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여
US20100240683A1 (en) Combination therapy, composition and methods for the treatment of cardiovascular disorders
KR20010033003A (ko) 스타틴-카르복시알킬에테르 병용 제제
TW201906605A (zh) 用於治療共核蛋白病的斯他汀組合物及方法
KR20110042108A (ko) 새로운 메틸렌디옥시 페놀 화합물 및 질병 치료에서 이들의 사용
US20070166321A1 (en) Compositions and Methods for Reducing Cholesterol and Inflammation
AU779631B2 (en) Method and compositions for inhibiting arteriosclerosis
JP2008063322A (ja) ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物
JPWO2001085155A1 (ja) 動脈硬化抑制方法及び組成物
US20080070938A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocysteine
CA2492781A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocystein
CN101068548B (zh) 用于减少、稳定富含脂质的斑块和/或防止富含脂质的斑块破裂的方法
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
JPWO2019216313A1 (ja) 心血管疾患に有用な医薬
Ballantyne et al. 1084-176 Efficacy of ezetimibe coadministered with simvastatin versus atorvastatin in patients with hypercholesterolemia
JP2025531272A (ja) Ｍａｐｋ経路変異に起因するがんの処置のためのｈｄａｃ阻害剤ｏｋｉ－１７９

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170703